[go: up one dir, main page]

BR9508196A - Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro - Google Patents

Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro

Info

Publication number
BR9508196A
BR9508196A BR9508196A BR9508196A BR9508196A BR 9508196 A BR9508196 A BR 9508196A BR 9508196 A BR9508196 A BR 9508196A BR 9508196 A BR9508196 A BR 9508196A BR 9508196 A BR9508196 A BR 9508196A
Authority
BR
Brazil
Prior art keywords
lipoxygenase
host
pharmaceutical composition
inflammatory diseases
treating inflammatory
Prior art date
Application number
BR9508196A
Other languages
English (en)
Inventor
Gurmit Grewal
Xiong Cai
Sajjat Hussoin
Aberra Fura
Ralph Scannell
Tesfaye Biftu
Changgeng Qian
Original Assignee
Cytomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,656 external-priority patent/US5792776A/en
Priority claimed from US08/390,641 external-priority patent/US6201016B1/en
Priority claimed from US08/454,600 external-priority patent/US5750565A/en
Priority claimed from US08/454,748 external-priority patent/US5703093A/en
Application filed by Cytomed Inc filed Critical Cytomed Inc
Publication of BR9508196A publication Critical patent/BR9508196A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9508196A 1994-06-27 1995-06-27 Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro BR9508196A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/265,656 US5792776A (en) 1994-06-27 1994-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/390,641 US6201016B1 (en) 1994-06-27 1995-02-17 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,600 US5750565A (en) 1995-05-25 1995-05-25 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,748 US5703093A (en) 1995-05-31 1995-05-31 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PCT/US1995/008213 WO1996000212A1 (en) 1994-06-27 1995-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
BR9508196A true BR9508196A (pt) 1997-09-02

Family

ID=27500861

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508196A BR9508196A (pt) 1994-06-27 1995-06-27 Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro

Country Status (17)

Country Link
EP (1) EP0770064B1 (pt)
KR (1) KR100276570B1 (pt)
CN (1) CN1151125C (pt)
AT (1) ATE253564T1 (pt)
AU (1) AU703756B2 (pt)
BR (1) BR9508196A (pt)
CA (1) CA2194064C (pt)
CZ (1) CZ372096A3 (pt)
DE (1) DE69532077T2 (pt)
EE (1) EE9600184A (pt)
FI (1) FI965123A7 (pt)
HU (1) HUT77773A (pt)
MX (1) MX9606635A (pt)
NO (1) NO965569L (pt)
PL (1) PL317873A1 (pt)
RU (1) RU2190607C2 (pt)
WO (1) WO1996000212A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502243A (ja) 1992-07-13 1996-03-12 サイトメッド,インコーポレイテッド 炎症性および免疫性疾患の治療のための2,5‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
AU3370099A (en) * 1998-03-31 1999-10-18 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
CA2345919A1 (en) 1998-07-03 2000-01-13 Gangavaram Vasantha Madhava Sharma Substituted oxygen alicyclic compounds, including methods for synthesis thereof
AU750592B2 (en) 1998-07-03 2002-07-25 Millennium Pharmaceuticals, Inc. Methods for synthesis of substituted tetrahydrofuran compound
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
CN100553636C (zh) 2000-08-04 2009-10-28 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
JP4674317B2 (ja) 2002-10-02 2011-04-20 ディエムアイ アクイジション コーポレイション 疾病の判定および監視
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
JP2007501243A (ja) * 2003-08-04 2007-01-25 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ctla4分子を用いる心臓血管疾患の治療方法
MXPA06008599A (es) * 2004-01-30 2006-08-28 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc-quimiocina.
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
CA2846464A1 (en) 2011-10-10 2013-04-18 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
ES2795803T3 (es) 2011-10-10 2020-11-24 Ampio Pharmaceuticals Inc Tratamiento de artropatía degenerativa
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
WO2014145729A2 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR101480674B1 (ko) * 2014-07-03 2015-01-09 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101503647B1 (ko) 2014-07-03 2015-03-18 주식회사 큐리언트 염증성 질환 치료용 약학적 조성물
KR101496095B1 (ko) * 2014-07-04 2015-03-03 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496094B1 (ko) 2014-07-04 2015-02-25 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496096B1 (ko) * 2014-07-17 2015-03-02 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
DE3778248D1 (de) * 1986-08-21 1992-05-21 Merck & Co Inc 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
EP0365089A3 (en) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
US5175183A (en) * 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
EP0465122A1 (en) * 1990-06-29 1992-01-08 Merck & Co. Inc. Process of making 2,5-diaryl tetrahydrofurans and analogs thereof useful as paf antagonists
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5110831A (en) * 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) * 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
US5420164A (en) * 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
US5183818A (en) * 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) * 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) * 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
JPH08502243A (ja) * 1992-07-13 1996-03-12 サイトメッド,インコーポレイテッド 炎症性および免疫性疾患の治療のための2,5‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
TW418089B (en) * 1993-08-19 2001-01-11 Pfizer Pharmaceutical composition comprising phenoxyphenyl cyclopentenyl hydroxyureas (the dextrorotary isomers)

Also Published As

Publication number Publication date
HU9603611D0 (en) 1997-02-28
WO1996000212A1 (en) 1996-01-04
ATE253564T1 (de) 2003-11-15
AU2914295A (en) 1996-01-19
EE9600184A (et) 1997-06-16
DE69532077T2 (de) 2004-09-02
EP0770064B1 (en) 2003-11-05
EP0770064A1 (en) 1997-05-02
HK1004396A1 (en) 1998-11-27
PL317873A1 (en) 1997-04-28
DE69532077D1 (de) 2003-12-11
FI965123A7 (fi) 1997-02-26
AU703756B2 (en) 1999-04-01
CN1151125C (zh) 2004-05-26
KR100276570B1 (ko) 2001-02-01
HUT77773A (hu) 1998-08-28
NO965569D0 (no) 1996-12-23
CZ372096A3 (cs) 1998-04-15
MX9606635A (es) 1997-12-31
CA2194064A1 (en) 1996-01-04
FI965123A0 (fi) 1996-12-19
NO965569L (no) 1997-02-17
RU2190607C2 (ru) 2002-10-10
EP0770064A4 (en) 1998-01-14
CN1163610A (zh) 1997-10-29
CA2194064C (en) 2009-03-17

Similar Documents

Publication Publication Date Title
BR9508196A (pt) Composto uso de compostos composição farmacêutica e processo para tratamento de doenças inflamatórias em hospedeiro
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
NO971684D0 (no) Nye benzoxazoler
FI20105844L (fi) Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
HUP0001539A2 (hu) 2-(1-Imino-etil-amino)-etil-homocisztein, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmények
BRPI0208957B8 (pt) composto, uso de um composto, composição farmacêutica e sal
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
DE69830504D1 (de) Antithrombotische mitteln
IL113894A (en) Oxalylamino-benzofuran- and benzothienyl- derivatives process for their preparation pharmaceutical compositions containing them and their use
AR019671A1 (es) Uso de una cantidad terapeuticamente efectiva de (+) norcisaprida o una sal farmacologicamente aceptable de la misma sustancialmente libre de su (-)estereoisomero, para la preparacion de un medicamento
CA2234642A1 (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
AU1185801A (en) Novel compounds
DK0650485T3 (da) 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser
NO974320L (no) Fucopeptider
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
MX9605203A (es) Nuevos compuestos glicomimeticos como antagonistas de selectinas y medicamentos que actuan inhibiendo las inflamaciones.
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
NO992009L (no) Nye trans-3,4-kromanderivater som kan anvendes ved forhindring eller behandling av °strogenrelaterte sykdommer eller syndromer
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
WO2000046193A3 (en) Ether derivatives having neuronal activity

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal